Very Early PCSK9 Inhibition for Acute Myocardial Infarction

Официальное название

Impact of PCSK9 Monoclonal Antibody Very Early Administered in Hospital to Reduce Cardiovascular Events in Acute Myocardial Infarction (IMMEDIATE -MI)

Обзор

Acute myocardial infarction (AMI) remains a major cause of morbidity and mortality, particularly in patients with multivessel coronary artery disease. Although primary percutaneous coronary intervention (PCI) has significantly improved short-term outcomes, these patients remain at high risk of recurrent cardiovascular events due to vulnerable non-culprit plaques. Coronary imaging techniques such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and angiography-derived indices (QFR, RWS) can identify high-risk lesions, but the optimal management strategy is still debated. Early and intensive lipid-lowering therapy has been shown to stabilize atherosclerotic plaques. PCSK9 monoclonal antibodies, in combination with statins, provide rapid and profound LDL-cholesterol reduction and may enhance plaque stabilization beyond standard therapy. Small imaging studies suggest favorable effects of PCSK9 inhibitors on fibrous cap thickness and lipid burden, but their impact on clinical outcomes in AMI patients with multivessel disease remains uncertain. This study aims to evaluate whether very early in-hospital administration of a PCSK9 inhibitor, in addition to standard care, can reduce major adverse cardiovascular events (MACE) over 12 months compared with standard lipid-lowering therapy alone. The trial will also explore imaging-based markers of plaque vulnerability and functional indices as secondary endpoints, in order to better understand the mechanisms linking lipid lowering, plaque stabilization, and clinical outcomes.

Вмешательства

• Препарат Standard Lipid-Lowering Therapy
  Participants will receive lipid-lowering therapy according to current clinical guidelines. Treatment will be initiated with statins. Based on follow-up lipid levels, ezetimibe may be added, and PCSK9 inhibitor therapy may be considered if LDL-C goals are not met.
• Препарат Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)
  Participants will receive early intensive lipid-lowering therapy with a PCSK9 monoclonal antibody, initiated during the index hospitalization, in addition to statins. Ezetimibe may be added if clinically indicated. The PCSK9 inhibitor will be administered regardless of baseline lipid levels.

Первичные конечные точки

• Incidence of Major Adverse Cardiovascular Events (MACE) at 12 Months [Срок оценки: 12 months after index percutaneous coronary intervention (±30 days)]

Вторичные конечные точки (6)

• Incidence of Key Secondary Cardiovascular Events [Срок оценки: 12 months after index PCI (±30 days)]
• Incidence of All-Cause Death [Срок оценки: 12 months after index PCI (±30 days)]
• Incidence of Non-fatal Myocardial Infarction [Срок оценки: 12 months after index PCI (±30 days)]
• Incidence of Non-fatal Ischemic Stroke [Срок оценки: 12 months after index PCI (±30 days)]
• Incidence of Unplanned Ischemia-Driven Revascularization [Срок оценки: 12 months after index PCI (±30 days)]
• Rehospitalization for Unstable Angina [Срок оценки: 12 months after index PCI (±30 days)]

Критерии участия

Критерии включения

• Age ≥18 years.
• Acute myocardial infarction (AMI) onset within 30 days (first hospitalization with a confirmed diagnosis of STEMI or NSTEMI).
• Multivessel coronary artery disease; successful percutaneous coronary intervention (PCI) of the culprit lesion in the infarct-related artery (IRA), including stent implantation and/or balloon angioplasty and/or thrombus aspiration.
• At least one angiographically assessed diameter stenosis ≥50% in a non-infarct-related artery (non-IRA) with a reference vessel diameter ≥2.5 mm.
• Able to understand and willing to provide written informed consent, comply with prescribed medical therapy, and complete the required follow-up.

Критерии исключения

• Cardiogenic shock or severe heart failure (Killip class IV).
• Serum creatinine >150 μmol/L or glomerular filtration rate (GFR) <45 mL/min/1.73 m² calculated by the Cockcroft-Gault equation.
• Known or suspected infective endocarditis or active systemic infection.
• Clinically significant coagulation abnormalities, or anticipated inability to tolerate long-term antiplatelet therapy.
• Pregnant or breastfeeding women, women planning pregnancy within 1 year, or those unwilling to use effective contraception.
• Expected survival <1 year.
• Allergy to iodinated contrast media.
• Prior coronary artery bypass grafting (CABG).
• Participation in another clinical trial within 3 months before enrollment, or current participation in another drug/device clinical trial without having reached its primary endpoint.
• Coronary angiography-based exclusion criteria:

10.1 Non-IRA lesion with visually estimated diameter stenosis >90% and TIMI flow ≤2; 10.2 Complex coronary artery disease requiring CABG; 10.3 Angiography unable to clearly identify the infarct-related artery or non-infarct-related arteries.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Zhongshan Hospital, Fudan University — Шанхай

Идентификаторы

NCT: NCT07208006 · KY2025169

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗